E. Romano, M. Rossi, G. Ratzinger, M. A. de Cos, D. J. Chung, K. S. Panageas, J. D. Wolchok, A. N. Houghton, P. B. Chapman, G. Heller, J. Yuan and J. W. Young, “Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation in Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells in Vivo,” Clinical Cancer Research, Vol. 17, No. 7, 2011, pp. 1984-1997. doi:10.1158/1078-0432.CCR-10-3421

has been cited by the following article:

• TITLE: Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  AUTHORS: Kristian M. Hargadon

  KEYWORDS: Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.3 No.2A, June 20, 2013

  ABSTRACT: Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.